Epidemiology and Health Technology

A common objective of this area is to generate and validate tools with clinical utility for the diagnosis, prognosis and treatment of different pathologies. The translational nature of the groups should be highlighted that allows collaborations with the majority of the Hospital's clinical services and transversal vocation backed by various collaborations with other IRYCIS groups.

Leaders

  • Dr. Javier Zamora Moreno

    Dr. Javier Zamora Moreno

    Bachelor and Doctor of Biology from the Complutense University of Madrid.

    Head of the Clinical Biostatistics Unit of the Ramón Hospital and Principal Investigator of the Epidemiology and Clinical Biostatistics Group. He is Head of the Research Group of the CIBER of Epidemiology and Public Health (CIBERESP), where he has been coordinator of the Scientific Program of Clinical Epidemiology. He is also Professor (Senior Lecturer) of Queen Mary University in London where he develops research in Maternal and Child Health. He has held responsibilities in the evaluation of the State Research Plan during the last years in different organizations (ANEP, ISCIII) and as an expert advisor to the EMA and the AEMPS. His lines of interest are related to research methodology and biostatistics mainly in the field of synthesis research (Systematic Reviews and Meta-analysis), prognostic and diagnostic research and evaluation of clinical practice. Author of more than 200 international articles with an h index of 44 (WoS) (62 in Google Scholars).

    Close

    Dr. Javier Zamora Moreno

    Biostatistics Unit Coordinator

    See CV
  • Dra. Laura García Bermejo

    Dra. Laura García Bermejo

    María Laura García Bermejo, PhD in Cell Biology & Genetics (1997, UA-CIB (CSIC), with 27 years of experience. She is a researcher at the Ramon y Cajal Institute for Health Research (IRYCIS) since 2002, Head of the Biomarkers and Therapeutic Targets group since 2008 and IRYCIS Scientific Deputy Director since February 2017. Her group has a translational and multidisciplinary nature, including basic and clinical researchers, also given rise to the Core Facility for Biomarkers and Therapeutic Targets, included in the IRYCIS Portfolio. Dr. García Bermejo is co-chair of the Biomarker Platform of EATRIS (European Infrastructure for Translational Research and Personalized Medicine). In the last 10 years, Dr. García Bermejo and her group have worked on the characterization of pathophysiological mechanisms responsible for renal pathologies, establishing new models in vitro and in vivo, which reproduce the clinical context. In particular, in recent years the group has been working on the identification and validation of new biomarkers and therapeutic targets based on non-coding RNAs, particularly miRNAs, in different pathologies, including nephropathies, cancer and cardiovascular and infectious diseases as well as liver pathologies. She is the author of more than 65 indexed international publications, 15 as correspondence author (iH 27, i10 40, 2654 citations), 3 book chapters and has participated in 58 projects, 15 international and 38 nationals being IP in 26 of them. She belongs to 5 national network consortiums and participates in 7 clinical trials. She is the inventor of 37 patents, supervisor of 10 Doctoral Theses and 4 Master's Thesis and reviewer for several national and international funding organizations.

    Close

    Dra. Laura García Bermejo

    Head of Group and Head of UCA IRYCIS

    See CV